Bile salt inhibition of host cell damage by Clostridium difficile toxins.
Virulent Clostridium difficile strains produce toxin A and/or toxin B that are the etiological agents of diarrhea and pseudomembranous colitis. Treatment of C. difficile infections (CDI) has been hampered by resistance to multiple antibiotics, sporulation, emergence of strains with increased virulence, recurrence of the infection, and the lack of drugs that preserve or restore the colonic bacterial flora. As a result, there is new interest in non-antibiotic CDI treatments. The human conjugated bile salt taurocholate was previously shown in our laboratory to inhibit C. difficile toxin A and B activities in an in vitro assay. Here we demonstrate for the first time in an ex vivo assay that taurocholate can protect Caco-2 colonic epithelial cells from the damaging effects of the C. difficile toxins. Using caspase-3 and lactate dehydrogenase assays, we have demonstrated that taurocholate reduced the extent of toxin B-induced apoptosis and cell membrane damage. Confluent Caco-2 cells cultured with toxin B induced elevated caspase-3 activity. Remarkably, addition of 5 mM taurocholate reduced caspase-3 activity in cells treated with 2, 4, 6, and 12 µg/ml of toxin B by 99%, 78%, 64%, and 60%, respectively. Furthermore, spent culture medium from Caco-2 cells incubated with both toxin B and taurocholate exhibited significantly decreased lactate dehydrogenase activity compared to spent culture medium from cells incubated with toxin B only. Our results suggest that the mechanism of taurocholate-mediated inhibition functions at the level of toxin activity since taurocholate did not affect C. difficile growth and toxin production. These findings open up a new avenue for the development of non-antibiotic therapeutics for CDI treatment.
The University of Texas School of Public Health, Division of Epidemiology, Human Genetics and Environmental Sciences, Center For Infectious Diseases, Houston, Texas, United States of America ; The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, United States of America.
Charles
C
Darkoh
Eric L
EL
Brown
Heidi B
HB
Kaplan
Herbert L
HL
DuPont
D001426:Bacterial Proteins / Q000302:isolation & purification / Q000378:metabolism* / Q000633:toxicity; D001427:Bacterial Toxins / Q000302:isolation & purification / Q000378:metabolism* / Q000633:toxicity; D001647:Bile Acids and Salts / Q000494:pharmacology*; D018938:Caco-2 Cells; D053148:Caspase 3 / Q000378:metabolism; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D016360:Clostridioides difficile / Q000187:drug effects* / Q000472:pathogenicity; D004761:Enterocolitis, Pseudomembranous / Q000378:metabolism; D006801:Humans; D013656:Taurocholic Acid / Q000494:pharmacology
D001426:Bacterial Proteins; D001427:Bacterial Toxins; D001647:Bile Acids and Salts; C031815:toxB protein, Clostridium difficile; D013656:Taurocholic Acid; D053148:Caspase 3